Search in:

Therapeutics and Clinical Risk Management Volume 13, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Jan Sperl1 Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine

Sona Frankova1 Department of Hepatogastroenterology, Institute for Clinical and Experimental MedicineCorrespondence[email protected]

Miluse Kreidlova2 Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital, Charles University

Dusan Merta3 Department of Anesthesiology, Resuscitation and Intensive Care, Institute for Clinical and Experimental Medicine

Monika Tothova4 Dialysis Center Motol, Fresenius Medical Care, Prague, Czech Republic

Julius Spicak1 Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine

Pages 733-738 | Published online: 22 Jun 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (13)

Radwa Samir Hagag, Morkoss Medhat Fakhry, Ossama Ashraf Ahmed, Shaimaa Abdalaleem Abdalgeleel, Mahasen Aly Radwan & Gina Gamal Naguib. (2022) Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. The Egyptian Journal of Internal Medicine 34:1.
Crossref

Sona Frankova, Zuzana Jandova, Gabriela Jinochova, Miluse Kreidlova, Dusan Merta & Jan Sperl. (2021) Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduction Journal 18:1.
Crossref

Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit & Ezequiel Ridruejo. (2021) Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 41:5, pages 578-589.
Crossref

Kasra Ghanaat, Heidar Sharafi & Seyed Moayed Alavian. (2021) The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urology Monthly 13:2.
Crossref

Sara Majd Jabbari, Khadije Maajani, Shahin Merat, Hossein Poustchi & Sadaf G. Sepanlou. (2021) An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLOS ONE 16:2, pages e0246594.
Crossref

Fadi Shehadeh, Markos Kalligeros, Katrina Byrd, Douglas Shemin, Eleftherios Mylonakis, Paul Martin & Erika M. C. D’Agata. (2020) Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Scientific Reports 10:1.
Crossref

Abdel‐Hameed Ibrahim Mohammed Ebid, Osama Ashraf Ahmed, Sara Hassan Agwa, Sara Mohamed Abdel‐Motaleb, Amira Mohamed Elsawy & Radwa Samir Hagag. (2019) Safety, efficacy and cost of two direct‐acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients. Journal of Clinical Pharmacy and Therapeutics 45:3, pages 539-546.
Crossref

Qunying Han, Xiude Fan, Xiaoyun Wang, Ye Wang, Huan Deng, Xiaoge Zhang, Kun Zhang, Na Li & Zhengwen Liu. (2019) High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virology Journal 16:1.
Crossref

Noha H. Habashy & Marwa M. Abu-Serie. (2019) Major royal-jelly protein 2 and its isoform X1 are two novel safe inhibitors for hepatitis C and B viral entry and replication. International Journal of Biological Macromolecules 141, pages 1072-1087.
Crossref

Ahmed Yahia Elmowafy, Hanzada Mohamed El Maghrabi, Khaled Farouk Eldahshan, Ayman Fathi Refaie, Mohammed Adel Elbasiony, Yasser Elsayed Matter, Hazem Hamed Saleh, Gamal Elsayed Shiha, Lionel Rostaing & Mohamed Adel Bakr. (2019) Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. International Urology and Nephrology 51:9, pages 1639-1647.
Crossref

Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC & Sanjay Hadigal. (2019) Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World Journal of Gastroenterology 25:29, pages 3897-3919.
Crossref

Sunil Taneja, Ajay Duseja, Arka De, Manu Mehta, Raja Ramachandran, Vivek Kumar, Harbir Singh Kohli, Krishan Lal Gupta, Radha Krishan Dhiman & Yogesh Chawla. (2018) Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Digestive Diseases and Sciences 63:5, pages 1334-1340.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Articles from other publishers (13)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Citations (13)

Articles from other publishers (13)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date